Tag results:

MAPK

LncPTSR Triggers Vascular Remodeling in Pulmonary Hypertension by Regulating [Ca2+]i in Pulmonary Arterial Smooth Muscle Cells

[American Journal of Respiratory Cell and Molecular Biology] A long non-coding RNA attenuated by platelet-derived growth factor BB was identified and its functional roles were investigated in vitro and in vivo.

ERK3-MK5 Signaling Regulates Myogenic Differentiation and Muscle Regeneration by Promoting FoxO3 Degradation

[Journal of Cellular Physiology] Researchers showed that genetic inactivation of extracellular signal-regulated kinase 3 impaired postnatal skeletal muscle growth and adult muscle regeneration after injury.

Blockade of the Pro-Fibrotic Reaction Mediated by the miR-143/-145 Cluster Enhances the Responses to Targeted Therapy in Melanoma

[EMBO Molecular Medicine] Scientists showed that the anti-fibrotic drug nintedanib was active to normalize the fibrous ECM network, enhanced the efficacy of MAPK-targeted therapy, and delayed tumor relapse in a preclinical model of melanoma.

The Yun/Prohibitin Complex Regulates Adult Drosophila Intestinal Stem Cell Proliferation through the Transcription Factor E2F1

[Proceedings of the National Academy of Sciences of the United States of America] From an RNA interference (RNAi) screen in adult Drosophila intestinal stem cells (ISCs), researchers identified a factor, Yun, required for proliferation of normal and transformed ISCs.

DDR1 Promotes Hepatocellular Carcinoma Metastasis through Recruiting PSD4 to ARF6

[Oncogene] Researchers found that discoidin domain receptor 1 (DDR1) was upregulated in HCC tissues, and the expression of DDR1 in TNM stage II-IV was higher than that in TNM stage I in HCC tissues, and high DDR1 expression was associated with poor prognosis.

Molecular Profile of FLT3-Mutated Relapsed/Refractory AML Patients in the Phase III ADMIRAL Study of Gilteritinib

[Blood Advances] Researchers provided insight into the relapsed or refractory (R/R) AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib across a wide spectrum of molecular and genetic subgroups in FLT3-mutated R/R AML.

Popular